Fatih Sultan Mehmet Training and Research Hospital,Istanbul,Turkey.
Fatih Sultan Mehmet Training and Research Hospital,Istanbul,Turkey.
Photodiagnosis Photodyn Ther. 2021 Dec;36:102582. doi: 10.1016/j.pdpdt.2021.102582. Epub 2021 Oct 11.
Our aim is to examine the effect of intravitreal aflibercept treatment on the choroidal vascularity index in eyes with neovascular age-related macular degeneration (nARMD) using the binarization method.
Included in the study were the 38 eyes of 38 patients diagnosed with nARMD and treated with intravitreal aflibercept at our clinic. The patients' 12-month records were reviewed retrospectively. Patients' choroidal thickness (CT) was measured at baseline, 3rd month, 6th month, and 12th month on EDI-OCT images. We calculated luminal area (LA), stromal area (SA), total choroidal area (TCA), and choroid vascular index (CVI) values using binarization.
The mean age of the patients was 70,1 ± 8 years. The mean of injections over 12 months was 5.6 ± 2. Baseline values were CT 224 µm, LA 0,214 mm, SA 0,119mm, TCA 0,333 mm, and CVI 64% respectively. At the 3rd month, values were CT 223 µm, LA 0,212 mm, SA 0,121 mm, TCA 0,332 mm, and CVI 64%, respectively. The 6th-month values were CT 221 µm, LA 0,204 mm, SA 0,116 mm, TCA 0,320 mm, and CVI 64%, respectively, and 12-month values were CT 218 µm, LA 0,204 mm, SA 0,112 mm, TCA 0,318 mm, and CVI 64%, respectively. According to LogMAR, BCVA was 0.59 at baseline, 0.56 at 3 months, 0.52 at 6 months, and 0.51 at 12 months. At the end of month 12, we observed a statistically significant decrease in CT. No significant changes were observed in other parameters. When the number of injections was correlated with CVI, CT, and BCVA, a significant negative correlation was observed with CVI CONCLUSIONS: Aflibercept treatment reduces CT by affecting not only luminal but also stromal areas of the choroid in the long term but does not change the CVI. However, as the number of injections increases, CVI decreases.
我们的目的是使用二值化方法检查玻璃体内注射阿柏西普治疗对新生血管性年龄相关性黄斑变性（nAMD）患者脉络膜血管指数的影响。
本研究纳入了在我院接受玻璃体内注射阿柏西普治疗的 38 例（38 只眼）nAMD 患者。回顾性分析了患者 12 个月的病历。在 EDI-OCT 图像上，于基线、第 3 个月、第 6 个月和第 12 个月测量患者的脉络膜厚度（CT）。我们使用二值化方法计算管腔面积（LA）、基质面积（SA）、总脉络膜面积（TCA）和脉络膜血管指数（CVI）值。
患者的平均年龄为 70.1±8 岁。12 个月内的平均注射次数为 5.6±2 次。基线值分别为 CT 224μm、LA 0.214mm、SA 0.119mm、TCA 0.333mm 和 CVI 64%。第 3 个月时，这些值分别为 CT 223μm、LA 0.212mm、SA 0.121mm、TCA 0.332mm 和 CVI 64%。第 6 个月时，这些值分别为 CT 221μm、LA 0.204mm、SA 0.116mm、TCA 0.320mm 和 CVI 64%，第 12 个月时，这些值分别为 CT 218μm、LA 0.204mm、SA 0.112mm、TCA 0.318mm 和 CVI 64%。根据 LogMAR，基线时 BCVA 为 0.59，第 3 个月时为 0.56，第 6 个月时为 0.52，第 12 个月时为 0.51。在第 12 个月结束时，我们观察到 CT 有统计学意义的下降。其他参数无显著变化。当注射次数与 CVI、CT 和 BCVA 相关时，与 CVI 呈显著负相关。
阿柏西普治疗可长期降低 CT，不仅影响脉络膜的管腔区域，还影响基质区域，但不会改变 CVI。然而，随着注射次数的增加，CVI 会降低。
